Press Releases

DALLAS, June 12, 2018 — The American Heart Association—the world’s leading voluntary organization dedicated to building healthier lives, free of cardiovascular diseases and stroke—announced today research grants totaling more than $28 million to the scientific teams that will create a new…
REDWOOD CITY, Calif., June 06, 2018 — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that its Bioflux device has won the prestigious MedTech Breakthrough…
ALISO VIEJO, Calif., May 31, 2018 — MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Premarket Approval (PMA) for the LVIS® and LVIS® Jr. stents for stent-assisted coil embolization of intracranial aneurysms. The LVIS® and LVIS® Jr…
WAYNE, N.J., May 25, 2018 — Getinge, a leading global provider of innovative medical technology, today announced results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study. The study evaluated the use of…
MILFORD, Mass. — May 29, 2018 — RenalGuard Solutions™, Inc., a medical device company focused on innovative fluid management technologies for the cardiac and vascular markets, today announced new clinical study results demonstrating the feasibility of using RenalGuard®-Guided Diuretic Therapy to…
DUBLIN — May 24, 2018 — Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2018, which ended April 27, 2018. The company reported fourth quarter worldwide revenue of $8.144 billion, an increase of 2.9 percent as reported, or 6.5 percent on an…
DUBLIN and PARIS — May 24, 2018 — Investigators today unveiled clinical data from the independently run Onyx 1-Month OCT Study, which showed strong early vessel healing in a patient population that contained a high percentage of patients with complex coronary artery disease who were implanted…
REDWOOD CITY, Calif., May 23, 2018 - Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris®…
PARIS, May 22, 2018 — HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most common form of heart disease, when compared to other commonly used non-invasive…
DUBLIN — May 16, 2018 — Medtronic plc (NYSE: MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions, which account for approximately 20 percent of all percutaneous coronary…
PASADENA, Calif., May 16, 2018 — The FH Foundation, a leading research and advocacy organization, today announced the launch of a new research study that aims to understand the willingness for individuals with a clinical diagnosis of familial hypercholesterolemia (FH) and their family members to…
DUBLIN and BOSTON — May 11, 2018 — Medtronic plc (NYSE:MDT) today announced new clinical study results demonstrating that an investigational algorithm, utilizing the accelerometer signal in the Micra(TM) Transcatheter Pacing System (TPS) may restore AV synchrony, improving cardiac function in…
Phillipsburg, NJ—INFINITT North America, an award-winning developer of image and data management solutions for healthcare, announced today that they have achieved certification from the American College of Cardiology (ACC), demonstrating that INFINITT Cardiology Suite-v. 1.0.8.1 meets NCDR…
MOUNTAIN VIEW, Calif., May 10, 2018 — AliveCor, the leader in artificial intelligence and FDA-cleared personal electrocardiogram (ECG) technology, today announced an important milestone in its work with Mayo Clinic on Long QT Syndrome (LQTS). In an abstract published today at the Heart Rhythm…
SEATTLE, May 9, 2018 — Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, including the Carnation Ambulatory Monitor ("CAM™"), the world's only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection…
CARLSBAD, Calif., May 8, 2018 — Acutus Medical®, a global heart rhythm technology company, today announced that the AcQMap® High Resolution Imaging and Mapping System has been utilized for the first time in U.S. patients. The company also revealed initiation of a new clinical study to evaluate…
STOCKHOLM, May 7, 2018 — In patients who have suffered from a heart attack, a large portion of heart cells die, which may cause heart failure and significant mortality and morbidity. The aim of the collaboration with the global biopharmaceutical company AstraZeneca is to develop new ways of…
May 04, 2018 | Submitted by: Abbott
ABBOTT PARK, Ill., May 3, 2018 — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. Advisor HD Grid employs a new design that allows physicians to see things differently, capturing and analyzing data in…
SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR…
Vienna, VA (April 25, 2017) — James K. Min, MD, FSCCT, has been selected for a five-year term as the new editor-in-chief of the Journal of Cardiovascular Computed Tomography (JCCT). He in turn has named Todd C. Villines, MD, FSCCT, as executive editor along with Gudrun Feuchtner, MD. JCCT is…
TITUSVILLE, N.J., April 27, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results of a real-world study showing that adults with type 2 diabetes initiated on INVOKANA® (canagliflozin) 300mg had significantly better blood glucose control, based on A1C…